210 related articles for article (PubMed ID: 15826528)
1. [Clinical and epidemiological study of disease caused by Mycobacterium kansasii in the metropolitan area of Bilbao, Spain].
Leal Arranz MV; Gaafar A; Unzaga Barañano MJ; Crespo Notario JA; Cisterna Cáncer R; García Cebrián F
Arch Bronconeumol; 2005 Apr; 41(4):189-96. PubMed ID: 15826528
[TBL] [Abstract][Full Text] [Related]
2. [Pulmonary disease caused by Mycobacterium kansasii. Analysis of 39 cases].
Garrós Garay J; García Cebrián F; Martín Saco G; Lorza Blasco JJ; Ruiz de Gordejuela E
Arch Bronconeumol; 2001 Jan; 37(1):27-34. PubMed ID: 11181227
[TBL] [Abstract][Full Text] [Related]
3. Mycobacterium kansasii and M. scrofulaceum isolates from HIV-negative South African gold miners: incidence, clinical significance and radiology.
Corbett EL; Hay M; Churchyard GJ; Herselman P; Clayton T; Williams BG; Hayes R; Mulder D; De Cock KM
Int J Tuberc Lung Dis; 1999 Jun; 3(6):501-7. PubMed ID: 10383063
[TBL] [Abstract][Full Text] [Related]
4. Pulmonary Mycobacterium kansasii infection in Israel, 1999-2004: clinical features, drug susceptibility, and outcome.
Shitrit D; Baum GL; Priess R; Lavy A; Shitrit AB; Raz M; Shlomi D; Daniele B; Kramer MR
Chest; 2006 Mar; 129(3):771-6. PubMed ID: 16537880
[TBL] [Abstract][Full Text] [Related]
5. Treatment with a macrolide-containing regimen for Mycobacterium kansasii pulmonary disease.
Moon SM; Choe J; Jhun BW; Jeon K; Kwon OJ; Huh HJ; Lee NY; Daley CL; Koh WJ
Respir Med; 2019 Mar; 148():37-42. PubMed ID: 30827472
[TBL] [Abstract][Full Text] [Related]
6. Mycobacterium kansasii: antibiotic susceptibility and PCR-restriction analysis of clinical isolates.
da Silva Telles MA; Chimara E; Ferrazoli L; Riley LW
J Med Microbiol; 2005 Oct; 54(Pt 10):975-979. PubMed ID: 16157553
[TBL] [Abstract][Full Text] [Related]
7. Incidence and molecular typing of Mycobacterium kansasii in a defined geographical area in Catalonia, Spain.
Santin M; Alcaide F; Benitez MA; Salazar A; Ardanuy C; Podzamczer D; Rufi G; Dorca J; Martin R; Gudiol F
Epidemiol Infect; 2004 Jun; 132(3):425-32. PubMed ID: 15188712
[TBL] [Abstract][Full Text] [Related]
8. [Clinical importance of Mycobacterium kansasii and evaluation of the need to identify nontuberculous mycobacteria].
Etxebarrieta M; Rodrigo A; Martín C; Ojer M; Ruz A; Dorronsoro I
Enferm Infecc Microbiol Clin; 2002 Mar; 20(3):113-6. PubMed ID: 11904083
[TBL] [Abstract][Full Text] [Related]
9. Mycobacterium kansasii pulmonary infection: a prospective study of the results of nine months of treatment with rifampicin and ethambutol. Research Committee, British Thoracic Society.
Thorax; 1994 May; 49(5):442-5. PubMed ID: 8016763
[TBL] [Abstract][Full Text] [Related]
10. Pulmonary Mycobacterium kansasii infection: comparison of the clinical features, treatment and outcome with pulmonary tuberculosis.
Evans SA; Colville A; Evans AJ; Crisp AJ; Johnston ID
Thorax; 1996 Dec; 51(12):1248-52. PubMed ID: 8994524
[TBL] [Abstract][Full Text] [Related]
11. [Nontuberculous mycobacterial infections of the lung].
Latshang TD; Lo Cascio CM; Russi EW
Ther Umsch; 2011 Jul; 68(7):402-6. PubMed ID: 21728159
[TBL] [Abstract][Full Text] [Related]
12. Non-tuberculous slow-growing mycobacterial pulmonary infections in non-HIV-infected patients in south London.
Davies BS; Roberts CH; Kaul S; Klein JL; Milburn HJ
Scand J Infect Dis; 2012 Nov; 44(11):815-9. PubMed ID: 23078529
[TBL] [Abstract][Full Text] [Related]
13. Mycobacterium kansasii and human immunodeficiency virus co-infection in London.
Klein JL; Corbett EL; Slade PM; Miller RF; Coker RJ
J Infect; 1998 Nov; 37(3):252-9. PubMed ID: 9892529
[TBL] [Abstract][Full Text] [Related]
14. Incidence and clinical implications of isolation of Mycobacterium kansasii: results of a 5-year, population-based study.
Bloch KC; Zwerling L; Pletcher MJ; Hahn JA; Gerberding JL; Ostroff SM; Vugia DJ; Reingold AL
Ann Intern Med; 1998 Nov; 129(9):698-704. PubMed ID: 9841601
[TBL] [Abstract][Full Text] [Related]
15. Mycobacterium kansasii: a cause of treatable pulmonary disease associated with advanced human immunodeficiency virus (HIV) infection.
Levine B; Chaisson RE
Ann Intern Med; 1991 May; 114(10):861-8. PubMed ID: 1673053
[TBL] [Abstract][Full Text] [Related]
16. Mycobacterium kansasii.
Johnston JC; Chiang L; Elwood K
Microbiol Spectr; 2017 Jan; 5(1):. PubMed ID: 28185617
[TBL] [Abstract][Full Text] [Related]
17. Mycobacterium kansasii pulmonary diseases in Korea.
Yim JJ; Park YK; Lew WJ; Bai GH; Han SK; Shim YS
J Korean Med Sci; 2005 Dec; 20(6):957-60. PubMed ID: 16361804
[TBL] [Abstract][Full Text] [Related]
18. [Infection due to Mycobacterium kansasii in Elche, Spain].
Rodríguez JC; Ayelo A; Ruiz M; López M; Royo G
Med Clin (Barc); 2003 Mar; 120(7):253-4. PubMed ID: 12623000
[TBL] [Abstract][Full Text] [Related]
19. Mortality prediction in pulmonary Mycobacterium kansasii infection and human immunodeficiency virus.
Marras TK; Morris A; Gonzalez LC; Daley CL
Am J Respir Crit Care Med; 2004 Oct; 170(7):793-8. PubMed ID: 15215152
[TBL] [Abstract][Full Text] [Related]
20. Mycobacterium kansasii infection in patients infected with the human immunodeficiency virus.
Pintado V; Gómez-Mampaso E; Martín-Dávila P; Cobo J; Navas E; Quereda C; Fortún J; Guerrero A
Eur J Clin Microbiol Infect Dis; 1999 Aug; 18(8):582-6. PubMed ID: 10517196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
